Different data support a role for the epidermal growth factor receptor (EGFR) pathway during liver regeneration and hepatocarcinogenesis. However, important issues, such as the precise mechanisms mediating its actions and the unique versus redundant functions, have not been fully defined. Here, we present a novel transgenic mouse model expressing a hepatocyte-specific truncated form of human EGFR, which acts as negative dominant mutant (DEGFR) and allows definition of its tyrosine kinase-dependent functions. Results indicate a critical role for EGFR catalytic activity during the early stages of liver regeneration. Thus, after two-thirds partial hepatectomy, DEGFR livers displayed lower and delayed proliferation and lower activation of proliferative signals, which correlated with overactivation of the transforming growth factor-b pathway. Altered regenerative response was associated with amplification of cytostatic effects of transforming growth factor-b through induction of cell cycle negative regulators. Interestingly, lipid synthesis was severely inhibited in DEGFR livers after partial hepatectomy, revealing a new function for EGFR kinase activity as a lipid metabolism regulator in regenerating hepatocytes. In spite of these profound alterations, DEGFR livers were able to recover liver mass by overactivating compensatory signals, such as c-Met. Our results also indicate that EGFR catalytic activity is critical in the early preneoplastic stages of the liver because DEGFR mice showed a delay in the appearance of diethyl-nitrosamine-induced tumors, which correlated with decreased proliferation and delay in the diethyl-nitrosamine-induced inflammatory process. Conclusion: These studies demonstrate that EGFR catalytic activity is critical during the initial phases of both liver regeneration and carcinogenesis and provide key mechanistic insights into how this kinase acts to regulate liver pathophysiology. (HEPATOLOGY 2016;63:604-619) See Editorial on Page 371 T he liver is a unique organ in displaying reparative response and regenerative capacity. However, prolonged liver regeneration as a consequence of Abbreviations: DEN, diethyl-nitrosamine; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; mRNA, messenger RNA; NADPH, reduced nicotinamide adenine dinucleotide phosphate; PH, partial hepatectomy; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; TGF-a/-b, transforming growth factor (a/b); TNF-a, tumor necrosis factor-a; uPA, urokinase-type plasminogen activator; WT, wild type.
Different data support a role for the epidermal growth factor receptor (EGFR) pathway during liver regeneration and hepatocarcinogenesis. However, important issues, such as the precise mechanisms mediating its actions and the unique versus redundant functions, have not been fully defined. Here, we present a novel transgenic mouse model expressing a hepatocyte-specific truncated form of human EGFR, which acts as negative dominant mutant (DEGFR) and allows definition of its tyrosine kinase-dependent functions. Results indicate a critical role for EGFR catalytic activity during the early stages of liver regeneration. Thus, after two-thirds partial hepatectomy, DEGFR livers displayed lower and delayed proliferation and lower activation of proliferative signals, which correlated with overactivation of the transforming growth factor-b pathway. Altered regenerative response was associated with amplification of cytostatic effects of transforming growth factor-b through induction of cell cycle negative regulators. Interestingly, lipid synthesis was severely inhibited in DEGFR livers after partial hepatectomy, revealing a new function for EGFR kinase activity as a lipid metabolism regulator in regenerating hepatocytes. In spite of these profound alterations, DEGFR livers were able to recover liver mass by overactivating compensatory signals, such as c-Met. Our results also indicate that EGFR catalytic activity is critical in the early preneoplastic stages of the liver because DEGFR mice showed a delay in the appearance of diethyl-nitrosamine-induced tumors, which correlated with decreased proliferation and delay in the diethyl-nitrosamine-induced inflammatory process. Conclusion: These studies demonstrate that EGFR catalytic activity is critical during the initial phases of both liver regeneration and carcinogenesis and provide key mechanistic insights into how this kinase acts to regulate liver pathophysiology. (HEPATOLOGY 2016; 63:604-619) See Editorial on Page 371 T he liver is a unique organ in displaying reparative response and regenerative capacity. However, prolonged liver regeneration as a consequence of chronic liver diseases produces the appearance of genetic/ epigenetic alterations that finally concur in the development of hepatocarcinogenesis. The epidermal growth factor receptor (EGFR/ErbB1) pathway plays an essential role in virtually all steps of these processes. 1 However, many questions remain unanswered. It is not well understood which of its two main functions (cell proliferation and survival) plays more essential roles during liver regeneration or hepatocarcinogenesis. Additionally, EGF/ EGFR and hepatocyte growth factor (HGF)/Met signaling play both redundant and specific roles in these phenomena. [2] [3] [4] Nevertheless, their specific mechanisms are not completely known. We previously reported that the EGFR pathway impairs the suppressor arm of the transforming growth factor-b (TGF-b) pathway in hepatocytes and liver tumor cells in vitro 5, 6 ; however, there is no evidence that this effect may be relevant in vivo. Furthermore, there is a lack of knowledge about how necessary the catalytic domain of the EGFR pathway is in its in vivo actions, which is very important for the design of therapeutic strategies targeting this pathway. It would be expected that the enzymatic phosphorylation capacity of the EGFR is essential. In this sense, targeting EGFR by small interfering RNA technology or inhibiting its enzymatic capacity with gefitinib produced similar effects in liver tumor cells. 7 However, it has been also proposed that hepatocyte priming during liver regeneration involves modulation of the EGFR-mediated growth responses without an increase in its receptor tyrosine kinase activity. 8 Taking all this into consideration, we decided to generate a new experimental animal model to explore the role of hepatocyte EGFR tyrosine kinase activity in liver regeneration and hepatocarcinogenesis. A transgenic animal was generated which expresses specifically in hepatocytes a truncated form of the human EGFR that lacks the intracellular catalytic domain (previously generated by Schlessinger's group 9 ). This truncated form is able to undergo EGF-induced dimerization with wild-type (WT) receptors, allowing the binding of EGFR ligands but acting as a negative dominant mutant. 10, 11 This model has the advantage, compared with the knockout mouse model, that the EGFR ligands bind to the receptors in the hepatocyte membrane and no excess of EGFR ligand is available to the nonparenchymal cells. Furthermore, only the intracellular domain of the EGFR is missed, which means that the specific role of the phosphorylation-dependent EGFR activity will be analyzed. Partial hepatectomy (PH) and diethylnitrosamine (DEN) treatment were performed to analyze the specific roles of the EGFR catalytic activity during liver regeneration and hepatocarcinogenesis.
Materials and Methods
Generation of Transgenic EGFR Mice and Hepatocyte Cell Lines. A complementary DNA coding for a truncated form of the human EGFR, lacking the kinase domain in its intracytosolic region (amino acids 654-1186), was cloned in transference bacterial artificial chromosome clone RP23-279P6 (kindly provided by Prof. Dr. G€ unther Sch€ utz, Molekularbiologie der Zelle I, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany) carrying Albumin locus and Chloramphenicol resistance gene. The truncated EGFR was introduced just in the ATG starting codon of the albumin gene, surrounded by 160 kb of the albumin chromosomal genomic sequence, as described (Fig. 1A) . EGFR (abbreviated as DEGFR) mice. (A) A complementary DNA coding for a truncated form of the EGFR that had a deletion in its intracytosolic region (amino acids 654-1186) was cloned in a transference plasmid under the control of a specific hepatocyte promoter formed by the albumin locus just before ATG of the albumin mouse gene. Three different lines of transgenic mice were established and named as 1000, 2000, and 4000, which presented different copy number of the transgene. (B) Left: Primary hepatocytes were isolated from WT and DEGFR of the two mouse lines that presented a higher transgene copy number and immortalized as described in Materials and Methods. Right: Levels of human EGFR transcripts in mice analyzed by qRT-PCR. Mean 6 standard error of the mean of three independent experiments. (C) Morphology of the isolated hepatocytes. (D) Response to heparin binding EGF-like growth factor in terms of EGFR phosphorylation (fetal bovine serum depleted medium) was attenuated in the Hep1DEGFR hepatocytes. Western blot analysis, a representative experiment of five is shown. (E) Differences in the response to heparin binding EGF-like growth factor (fetal bovine serum depleted medium) in terms of cell proliferation between WT and Hep1DEGFR hepatocytes. Cell number was analyzed by trypan blue staining. Mean 6 standard error of the mean of two independent experiments performed in triplicate. (B,E) Student t test was used: *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: BAC, bacterial artificial chromosome; cDNA, complementary DNA; HB-EGF, heparin binding EGF-like growth factor.
Linearized bacterial artificial chromosome DNA was microinjected into the pronuclei of mouse B6CBAF2 zygotes according to reported protocols, 13 which were later transferred to pseudopregnant recipient females, finally obtaining transgenic mice Alb-D EGFR (from now abbreviated as DEGFR). Six different founder mice were bred with C57BL/6 WT mice. Three of them gave littermates and showed germline transmission of the transgene. The DEGFR F1 mice obtained were interbred to generate stable transgenic mouse lines, which were kept heterozygous. Transgenic lines are archived in the European Mouse Mutant Archive as B6CBA-Tg(Alb-deltaEGFR). Genotyping was assessed by polymerase chain reaction as specified in the European Mouse Mutant Archive. Using specific primers that exclusively detect expression of the human EGFR gene, we demonstrated the transgene expression in DEGFR mice by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis, which was confirmed at the protein level by western blot (Supporting Fig. S1 ).
For generation of immortalized hepatocytes, pools of four to six livers from WT and DEGFR neonates (5-7 days old) were used. Isolation of the cells (by collagenase dispersion) and immortalization were achieved as described. 14 For further details, culture conditions, cell viability, and apoptosis analyses, see the Supporting Information.
PH in Mice. PH was performed in animals at 8-12 weeks of age by removal of two-thirds of the liver, as described by Higgins and Anderson. 15 Mice were killed at 6, 12, 24, 48, and 72 hours and 7 days after surgery; and tissue samples were immediately frozen in liquid nitrogen for RNA and protein extraction, cryopreserved in optimal cutting temperature compound for oil red O staining, or fixed in 4% paraformaldehyde for immunohistochemical analysis. Sham-operated mice were used as control.
DEN-Induced Hepatocarcinogenesis in Mice. Male mice at day 15 of age received intraperitoneal injections of DEN (10 mg/kg) diluted in saline buffer. At 9 and 12 months of age, mice were sacrificed and their livers removed. For histological studies, liver lobes were fixed in 4% paraformaldehyde overnight and paraffin-embedded for immunohistochemical staining. Total RNA and protein were isolated from frozen tissues for qRT-PCR and western blotting analyses. Three to four animals/condition and at least two different tissue pieces/animal were processed for RNA extraction.
Western Blot Analysis. Total protein extracts and western blotting procedures were carried out as described. 16, 17 For more details and other methods, ethics statement, and statistical analysis, see the Supporting Information.
Results
Generation of Transgenic Mice Expressing a Truncated Form of the EGFR, Which Lacks the Catalytic Intracellular Domain in Hepatocytes. Three different lines of transgenic mice were established from founder mice expressing different copy numbers of the transgene (Fig. 1A) . Primary hepatocytes were isolated and immortalized, as described above. EGFR messenger RNA (mRNA) expression levels were proportional to the copy number of the transgene (Fig. 1B) . Analysis of cell morphology revealed that hepatocytes from line 1000 (highest expression of the transgene) presented lower viability (Fig. 1C ) and decreased basal proliferative capacity compared with the WT ones. Response to heparin binding EGF-like growth factor was significantly attenuated in terms of EGFR phosphorylation/ signaling, at either short ( Fig. 1D ) or long (results not shown) time points, as well as in terms of cell proliferation (Fig. 1E ). TGF-b transactivates the EGFR in hepatocytes, which inhibits its proapoptotic activity. 7, 18 Hepatocytes isolated from DEGFR mice did not phosphorylate the EGFR under TGF-b treatment, which correlated with impairment in the activation of survival signals, such as extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases (Supporting Fig. S2A ), higher growth inhibition, and apoptosis (Supporting Fig. S2B-D) . Interestingly, DEGFR hepatocytes showed higher basal apoptosis compared with WT ones. These results indicate the suitability of the animal and cell model to study the specific implication of the hepatocyte EGFR catalytic domain in liver physiology and pathology.
DEGFR Mice Show Delayed Hepatocyte Proliferation After Two-Thirds PH Coincident With a Higher Activation of the TGF-b Pathway. To explore the specific role of hepatocyte EGFR activity during liver regeneration, we performed two-thirds PH in WT and DEGFR mice, selecting the two mouse lines with a higher expression of the transgene. WT animals activated the EGFR pathway in the remaining liver after PH, analyzed as EGFR phosphorylation in hepatocytes by immunohistochemical analysis of paraffined tissues ( Fig.  2A) . DEGFR animals, in contrast, did not show phosphorylation of the EGFR. This was not due to differences in expression of the endogenous EGFR or its ligand TGF-a, the EGFR ligand highly expressed in hepatocytes during liver regeneration 19 (Supporting Fig. S3A ), which proves that the human DEGFR transgene indeed acts as a negative dominant, inhibiting the hepatocyte response to EGFR ligands. No compensatory increases in the expression of other members of the EGFR family (Erbb2, Erbb3, and Erbb4), due to inactivation of the EGFR function, were found (Supporting Fig. S3B ). Immunohistochemical analysis of Ki67 revealed lower and delayed hepatocyte proliferation in DEGFR mice (Fig. 2B) . WT animals showed an early increase in the levels of intracellular signals that mediate hepatocyte (A-C) Data are mean 6 standard error of the mean of at least four animals per group. Student t test was used: *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviation: A2m, a 2 -macroglobulin.
proliferation, such as p-AKT and p-ERK mitogen-activated protein kinases (Fig. 2C) . However, DEGFR livers presented a significantly lower response. Cytokines such as interleukin-6 and tumor necrosis factor-a (TNF-a) are considered relevant for priming hepatocytes to proliferate [2] [3] [4] ; however, both WT and DEGFR livers showed similar changes in the expression of these cytokines at 12-24 hours after PH, which correlated with a similar inflammatory response (results not shown).
Considering the relevant role played by EGF in counteracting the TGF-b suppressor effects, 6 we wondered whether DEGFR animals may show higher Smads phosphorylation and/or higher activation of TGF-b downstream pathways. Results indicated that Smad3 phosphorylation, a hallmark of TGF-b activation, is higher in DEGFR animals at basal levels and at all the times analyzed after PH ( Fig. 3A; Supporting Fig. S4) . Interestingly, the decrease in Smad3 phosphorylation observed in WT animals at 12 hours after PH was not observed in DEGFR mice, which maintained a high activation of the pathway. Levels of TGF-b1 transcripts were significantly higher in DEGFR livers before PH as well as at short times after PH compared with WT ones (Fig. 3B, left) . Furthermore, a 2 -macroglobulin, a plasma protein previously proposed as a binding protein for TGF-b that attenuates its effects, 20 was up-regulated in WT, but not in DEGFR, animals after PH (Fig. 3B  right) . Indeed, the EGFR pathway may up-regulate a 2 -macroglobulin, which could in turn counteract TGF-b activity. All these data suggest a stronger activation of the TGF-b pathway in DEGFR livers compared with WT ones.
As in vitro experiments had indicated that EGF counteracts TGF-b-induced apoptosis by inhibiting its effects on Bim and Bmf up-regulation, 7 we tested for potential differences in the expression of these genes between WT and DEGFR mice. Bmf, but not Bim, expression was down-regulated after PH in both animals; but, interestingly, levels remained higher in DEGFR compared with WT mice (Fig. 3C) . Expression of Bcl-x L , an antiapoptotic Bcl-2 member known to be a TGF-b target gene in hepatocytes, 6 increased early after PH in both animal models, although the increase in DEGFR mice was slightly lower. However, in spite of these differences, analysis of the active form of caspase-3 by immunohistochemistry or caspase-3 activity in tissues revealed no differences between WT and DEGFR livers at any of the different times analyzed (Supporting Fig. S5 ). Because Bim and Bcl-x L expression undergoes also posttranscriptional regulation, we analyzed their protein levels; but we could not find significant differences between WT and DEGFR mice (results not shown). Additionally, we searched for changes in the expression of Nox4, a reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase whose expression is up-regulated by TGF-b and mediates its apoptotic actions, 21 an effect that is impaired by EGF. 5 Nox4 expression significantly decreased after PH, as we have recently described. 22 However, no significant differences were observed between WT and DEGFR animals (Fig. 3C) .
As apoptosis failed to explain the observed delay in the hepatocyte proliferative response, we next focused on the expression of cell cycle regulators modulated by TGF-b. We found a significant increase in the expression of Cdkn2b (the gene encoding p15INK4b) at 6 hours after PH in DEGFR mice that was not observed in WT animals (Fig. 3C) . Levels of Cdkn1a transcripts (the gene encoding p21/WAF1/CIP1) increased at short times after PH in both animals, but whereas in WT animals levels slowly returned to basal ones, in DEGFR mice levels remained high, the differences being particularly relevant at 72 hours after PH. These results suggest that high levels of p15 could be responsible for the delay in the early proliferative response of DEGFR hepatocytes to PH and that high levels of p21 at later times could slow the proliferation during the entire regenerative process. Interestingly, both p15 and p21 levels were increased in nonhepatectomized DEGFR livers compared with WT ones. Indeed, a functional EGFR pathway may be necessary to counteract the cytostatic effects of TGF-b in hepatocytes, a process that is particularly crucial after two-thirds PH of the liver.
Regulation of Lipid Metabolism After Two-Thirds PH Is Altered in DEGFR Mice. When histological analysis by hematoxylin and eosin was performed, we observed that WT livers 48 hours after PH showed vacuolated cells, with the appearance of multifocal drops (Fig. 4A) , whereas DEGFR livers did not show this appearance. Suspecting that they could be deposits of lipids, we performed oil red O staining, confirming the accumulation of lipid drops, which correlated with an increase in triglyceride levels in WT, but not in DEGFR, livers (Fig. 4B,C) . Among different regulatory genes analyzed, the increase in lipid accumulation in WT livers was coincident with up-regulation of the mRNA levels of fatty acid synthase, a key enzyme involved in de novo fatty acid synthesis, and glucose-6-phosphate dehydrogenase, the regulatory enzyme of the pentosephosphate cycle, responsible for NADPH production. However, up-regulation of these enzymes was altered in DEGFR animals (Fig. 4D) . These results suggest that the EGFR pathway regulates lipid metabolism in hepatocytes after PH. Regardless of the described alterations, DEGFR mice showed only a slight, but not significant, increase in the mortality after two-thirds PH (Fig. 5A) . Remaining animals overcame liver injury (analyzed by serum parameters; Supporting Table S2 ) and were able to fully regenerate the liver with a similar kinetic to WT animals (Fig. 5B) . These results led us to state that in spite of the delay in hepatocyte proliferation, the capacity of the liver to recover its mass was not affected by the inhibition of EGFR signaling. Hence, we focused on identifying other potential mitogenic signals that could be overactivated in DEGFR livers. We observed that DEGFR mice expressed higher levels of Hgf mRNA than WT mice, both under basal conditions and shortly after PH (Fig.  5C, left) . Interestingly, we also found differences in the expression of urokinase-type plasminogen activator (uPA), which mediates the release of HGF from extracellular matrix during liver regeneration. 23 uPA mRNA levels were elevated in DEGFR livers, compared with WT mice, this difference being particularly significant at 6 hours after PH (Fig. 5C, right) . The increase in Hgf expression correlated with higher levels of c-Met phosphorylation in DEGFR livers. Notably, levels of phosphorylated c-Met remained high at 3 days after PH in DEGFR livers (Fig. 5D) . It is worth noting that, although c-Met mRNA levels decreased after PH in both WT and DEGFR livers (Fig. 5E ), the decrease in protein levels was only observed in WT animals, whereas DEGFR mice maintained, or even increased, c-Met levels at all time points analyzed (Fig. 5D ). This suggests that a posttranscriptional regulation of c-Met may allow the maintenance of high protein levels after PH in DEGFR mice, resulting in a sustained activation of this pathway. All these results indicate that the HGF Supporting Fig. S6 ) using ImageJ software. (B,C,E,F) Data are mean 6 standard error of the mean of at least three animals per group. Student t test was used: *P < 0.05, **P < 0.01, and ***P < 0.001. pathway is overactivated in DEGFR livers after PH and could justify that, although delayed, an efficient regeneration is observed in these animals.
It is worth mentioning that hepatocyte size significantly decreased at short times after PH in both WT and DEGFR animals; however, DEGFR mice showed a quick recovery of size such that after 24 hours hepatocyte size in DEGFR livers was significantly higher than that observed in WT livers (see Supporting Fig. S6 for images of the cells and Fig. 5F for quantification of the size). This hypertrophy could also contribute to the maintenance of liver functions and the low percentage of failure observed in DEGFR mice.
DEGFR Mice Show Delayed Appearance of Liver Tumors Induced by DEN Treatment. When we submitted 15-day-old WTand DEGFR mice to an acute treatment with DEN, liver injury (analyzed by serum parameters; Supporting Table S2 ) was higher in DEGFR animals, indicating a role for EGFR as a survival pathway in hepatocytes when submitted to a toxic insult. However, at 9 months of age, WTanimals developed macroscopically visible tumors, which were barely observed in DEGFR mice (Fig. 6A,B) . Consistently, the liver to body weight ratio significantly increased in WT, but not in DEGFR, mice (Fig. 6C) . However, 12 months after DEN injection, DEGFR animals presented macroscopic tumors (Fig.  6A,B) , and the liver to body weight ratio increase was quite similar in mice of both phenotypes (Fig. 6C) . Expression of the truncated form of the hEGFR was maintained at this age in the DEGFR animals, which did not show changes in the mRNA levels of any of the EGFR family members (Supporting Fig. S7 ).
Immunohistological and proliferative (Ki67 staining) analysis of tissues at 9 months after DEN treatment revealed the appearance of early preneoplastic lesions detectable only under the microscope. The number of lesions at 9 months of age in WT mice was much higher than that in DEGFR ones (Fig. 6D) . Analysis of cell proliferation rate by Ki67 immunohistochemistry in the neoplastic areas revealed a lower proliferative rate in DEGFR tumors at 9 months compared with WT tumors but a similar proliferative rate at 12 months of qRT-PCR analysis of mRNA levels of the proinflammatory cytokines interleukin-6 (Il6) and TNF-a (Tnfa) and chemokines CCL2 (Ccl2) and CXCL1 (Cxcl1) in macroscopically selected tumoral areas as well as in the surrounding tissue at 9 months of age in WT and DEGFR animals. (A,B) Data are mean 6 standard error of the mean of at least four animals per group (three sections/animal). Student t test was used: *P < 0.05 and **P < 0.01 compared to WT mice; #P < 0.05 compared to 9 months. Abbreviation: H&E, hematoxylin and eosin.
age (Fig. 7A) . These results suggest that lack of the catalytic activity of the EGFR delays the appearance of tumors but cannot fully prevent the hepatocarcinogenic process.
DEN-Induced Hepatic Inflammatory Process Is Delayed in DEGFR Mice. Considering that hepatocellular carcinoma (HCC) is a clear example of inflammation-related cancer, we evaluated inflammatory markers in histological sections of nontumoral areas of WT and DEGFR livers. As shown in Fig. 7B , WT livers showed strong positive areas for F4/80 staining, a macrophage marker, 9 months after DEN treatment, while DEGFR mice did not. At 12 months of age the situation in WT and DEGFR livers was comparable as both animals showed similar extent of inflammation. Furthermore, some fibrotic areas could be observed at 9 months of age in WT mice, whereas in DEGFR mice collagen deposits were only seen around the portal triads and perivascular regions (Supporting Fig. S8 ), as occurs in healthy liver. Larger collagen deposits were found in DEGFR livers at 12 months of age, similar to the situation in WT animals. These results indicate that lack of EGFR catalytic activity in the hepatocytes provokes a delay in the DEN-induced inflammatory process in the liver. Analysis of the expression of classical cytokines involved in liver inflammation revealed lower Il6 and TNFa mRNA levels (Fig. 7B ) but no changes in Il1b or Il17a (results not shown) in the tumor-surrounding tissues of DEGFR livers compared with WT ones. Furthermore, among different inflammatory chemokines for which some evidence exists that may be controlled by the EGFR pathway in HCC, 24 we found decreased expression of Ccl2 in the tumoral tissues and of Cxcl1 in both tumoral and nontumoral areas in DEGFR livers (Fig. 7B) . No differences were found in other analyzed chemokines (Ccl20, Cxcl2, Cxcl3, or Cxcl5; results not shown).
Following the previous hypothesis about crosstalk between TGF-b and the EGFR, we next analyzed the expression of TGF-b1 mRNA and the levels of phosphorylation of Smads in livers from WT and DEGFR mice at 9 months of DEN treatment. We could not find significant differences in either TGF-b1 levels (Fig. 8A) or phospho-Smad3 levels (results not shown). Of relevance, none of the apoptosis or cell cycle regulatory genes analyzed showed differences in DEGFR livers (in either tumor or surrounding areas) that could correlate with their lower tumor progression (Fig. 8A) . Nonetheless, it was really interesting to find a significant difference in the levels of Nox4, the NADPH oxidase that mediates some of the suppressor actions of TGF-b and for which we have recently found a relevant liver tumor suppressor role. 22 Finally, analysis of Hgf mRNA levels revealed a significant increase in the livers of DEGFR mice (nontumoral tissue). No evidence was observed for increases in uPA or Met at the mRNA level (Fig. 8B) . These results together indicate that delay in the inflammation process is the most evident alteration observed in DEGFR mice that justifies the retarding of the appearance of DEN-induced tumors. The increased levels of Nox4, a liver growth suppressor protein, could also contribute. The increase in HGF levels might replace the EGF-induced growth once the tumor is formed.
Discussion
The purpose of this study was to elucidate the specific role of the EGFR catalytic activity in a physiological (liver regeneration) and a pathological (hepatocarcinogenesis) situation of the liver where proliferation of adult hepatocytes takes place. Our results demonstrate that although EGFR signaling plays crucial roles in these processes, its absence only results in an overall delay in both regeneration and carcinogenesis, suggesting the existence of at least partial functional compensation by alternative routes.
First of all, we propose an essential role for EGFR in the early phases of the regenerative response after PH in mice, mediating a fast and efficient process. In a previous study, Natarajan et al.
25 generated a mouse model carrying a floxed EGFR allele to inactivate the EGFR in the adult liver. They proposed that EGFR is a critical regulator of hepatocyte proliferation in the initial phases of liver regeneration. Here, we confirm these results using a novel and unique animal model, but we also associate these effects with the catalytic activity of the EGFR and provide new insights about the molecular mechanisms by which this occurs, particularly overactivation of the TGF-b pathway and alterations in lipid metabolism.
Inactivation of TGF-b signaling in hepatocytes results in an increased proliferative response after PH. 26, 27 One of the main effects of TGF-b in liver cells is the induction of apoptosis through up-regulation of Bim and Bmf, proapoptotic members of the Bcl-2 family. The EGF pathway counteracts TGF-b proapoptotic effects by impairing up-regulation of both genes and upregulating Bclx L and Mcl-1, two antiapoptotic members of the Bcl-2 family, 6, 7 an effect mediated by survival signals such as the phosphoinositide 3-kinase/Akt and ERK pathways. However, our study demonstrates that the major role of EGF during liver regeneration after PH is not cell survival, probably because apoptosis is not relevant in a model where there is no hepatocyte damage. In contrast, the decrease and delay in activation of the phosphoinositide 3-kinase/Akt and ERK pathways at early times after PH in DEGFR animals, concomitant with high expression of the cyclin-dependent kinase inhibitor p15INK4, suggest a relevant role for the EGFR pathway in priming hepatocytes to enter into the cell cycle. We suggest that this delay could be related, at least partially, to the overexpression of TGFb1 and overactivation of the TGF-b pathway observed in animals with attenuated EGFR signaling. Although initially it was supposed that TGF-b could play a relevant role in mediating termination of liver regeneration, the latest results indicate that it is not necessary during this stage. 26 In contrast, a higher and accelerated DNA synthesis peak after PH was found in a Tgfbr2 knockout (R2LivKO) animal model. 26 Indeed, in contrast to previous predictions, TGF-b could play an essential role in the first stages of liver regeneration; and here we show that the EGFR pathway may be essential in regulating its expression and signaling.
It is well known that after PH hepatocellular fat accumulation occurs, concomitant with up-regulation of genes related to the adipogenic program, 28 which has been suggested to be a mammalian target of rapamycindependent process. 29 Disruption of hepatic adipogenesis is associated with impaired hepatocellular proliferation following PH 28 (for review, see Rudnick and Davidson 30 ). Here we show for the first time that the EGFR pathway is required for fat accumulation and upregulation of two key enzymes related to the de novo lipid synthesis. Further studies will be required to determine the precise molecular mechanisms mediating these effects.
In spite of these alterations, most of the DEGFR mice survived to the PH and no significant differences could be observed in the serum parameters related to liver injury or in the liver to body mass ratio. It is true that a higher mortality was observed in the first 48 hours after PH, as also suggested by Natarajan et al. in the mice carrying a floxed EGFR 25 ; but differences were not statistically significant. Our results are in agreement with the work of Michalopoulos's group where the consequences of in vivo silencing of the EGFR on rat liver regeneration using EGFR-specific short hairpin RNAs were analyzed. 31 Despite suppression of hepatocyte proliferation lasting into day 3 after PH, liver restoration occurred. Interestingly, hepatocytes in short hairpin EGFRtreated rats were considerably larger compared with short hairpin RNA-treated controls, an effect that we also observed in the DEGFR animals. Furthermore, we show that DEGFR mice presented higher phosphorylation levels of c-Met that could compensate for the lack of EGFR-mediated proliferative signals, a possibility that was also suggested in Michalopoulos et al.'s work. 31 Interestingly, we demonstrate up-regulation not only of the expression of Hgf in DEGFR livers after PH but also of its activator uPA, whose deficiency was shown to retard liver regeneration by impairing the HGF pathway. 23 However, even though the HGF/Met pathway is clearly overactivated in DEGFR animals, the contributions made by EGFR are unique in some aspects and not compensated by c-Met. In particular, early activation of phosphoinositide 3-kinase/Akt and ERK signaling would require EGFR signaling. Interestingly, Factor et al. elegantly demonstrated that c-Met signaling in hepatocytes is essential for sustaining long-term ERK1/2 activation throughout liver regeneration, and alternative pathways may account for the early ERK1/2 activation. 32 Furthermore, here we show that compensation of the cytostatic effects of the TGF-b pathway and regulation of lipid metabolism after PH appear to be fully dependent on EGFR and may be necessary for more efficient liver regeneration but dispensable for restoring liver mass in those animals that survive the first hours after PH. In agreement with these results, lack of Nogo-B (reticulon 4B) produces overactivation of the TGF-b pathway after PH in mice, coincident with a delay in hepatocyte proliferation, but did not affect the liver to body mass ratio in the regenerative process. 33 We also show here that attenuation of EGFR catalytic activity induces a significant delay in the appearance of tumorigenic lesions in DEN-treated animals. However, once tumors appear, the proliferative rate is similar in DEGFR and WT animals. Surprisingly, no significant differences were observed in the TGF-b pathway or in the expression of apoptosis or cell cycle regulatory genes, which could justify the delay in tumorigenesis. The only significant change was the mRNA levels of Nox4, a member of the NADPH oxidase family that is downregulated in HCC patients and negatively modulates hepatocyte proliferation. 22 Interestingly, EGF inhibits Nox4 expression, acting at the transcriptional level on the Nox4 promoter. 21 Indeed, the more significant difference lies in the appearance of preneoplastic lesions. In agreement with this result, a previous study using gefitinib (an EGFR inhibitor) in DEN-induced hepatocarcinogenesis in mice revealed that the gefitinib-treated animals showed significantly lower numbers of HCC nodules but that the mean tumor size was not different between untreated and gefitinib-treated mice. 34 Similar to what was found during liver regeneration, levels of HGF were much higher in DEGFR animals, which suggests that this cytokine might replace the mitogenic function of the EGFR ligands.
Our study indicates that the delay in the appearance of tumoral lesions might be associated with attenuation of the inflammatory process. In support of these results, pharmacological inhibition of EGFR signaling effectively prevented the progression of cirrhosis and regressed fibrosis in animal models. 35 EGFR signaling has been proposed as a critical junction between inflammation-related signals and potent cell regulating machineries. 36 Recent evidence indicates that the EGFR pathway regulates the expression of inflammatory factors and chemokine ligands produced by liver tumor cells. 24 Our results indicate differences in the expression of interleukin-6 and TNF-a in the tumor surrounding tissue, which suggests that the transgene expression in hepatocytes affects the production of inflammatory cytokines by themselves or other surrounding cells. Interestingly, the EGFR pathway plays an essential role in liver macrophages to mediate the inflammatory process in DEN-induced HCC. 37 Indeed, we cannot exclude that the overexpression of a truncated form of the EGFR that binds its ligands, but does not transduce the signal, may decrease the number of free EGFR ligands able to act on the nonparenchymal cells. Furthermore, it is worth pointing out that CCL2, a chemokine considered to be a central coordinator of hepatocyte-mediated inflammation, 38 showed decreased expression in DEGFR tumors. Finally, CXCL1, considered a critical player in both inflammation and tumor growth in HCC, 39 presented significantly decreased mRNA levels in DEGFR tumoral and nontumoral areas. Regardless of the mechanism and considering together our results and others in the literature, there is no doubt that one of the most essential functions of the EGFR pathway during hepatocarcinogesis should be regulation of inflammation addressed by parenchymal and/or nonparenchymal cells.
In conclusion, here we provide a novel research tool, a DEGFR transgenic mouse model, which has proved to be very useful in deciphering the molecular mechanisms underlying the functions of EGFR signaling in the adult liver, in particular uncovering its tyrosine kinasedependent functions in liver regeneration and carcinogenesis. We believe this model will open new possibilities for exploring the EGFR pathway as a targeted therapeutic strategy in chronic liver diseases and carcinogenesis.
